No abstract

No abstract

No abstract

Fear of crime (FoC) has dominated the political landscape over the last 20 years, with many crime policy developments during this period linked not to actual experiences of violence but to the fear of victimization. Fear of crime studies, in most cases, are conducted with populations that have only a passing, mediated knowledge of crime victimization. The research discussed in this article, in contrast, considers the impact of FoC with a highly victimized community, and establishes psychometric testing to validate an instrument to measure the impact of that fear ( Fear of Heterosexism Scale [ FoHS]). If FoC is related to experiences of crime as the existing research suggests, then victims of heterosexist prejudice, discrimination, and/or violence would be more likely to fear such incidents in the future. It was also predicted that participants who concealed their sexual and/or gender identity and had lower levels of social connectedness would experience higher levels of fear. The findings highlight the importance of contextual factors in FoH, and identify the critical roles that disclosure and social connectedness play in ameliorating the damaging effects of heterosexist victimization.

During the first ten years of a group started in February 1977 by the Avon Probation Service for the treatment of non-violent sex offenders, many of the offenders have shown a high degree of commitment to the group, and attendance levels have run consistently at over 70%. Of 63 men who came to the group during the ten-year study period, 33 completed their stay at the group, 11 left the group prematurely, and 11 never engaged satisfactorily. The remaining eight were still attending the group at the end of the study period. Of the 55 men whose contact with the group had ended, 36 (65%) had not been convicted of further sex offences by the end of the study period.

No abstract

No abstract

SUMMARY Seventy-six patients with advanced gastric adenocarcinoma were studied in a prospective, randomised, controlled trial using vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil in an initiation course and mitomycin-C with 5-fluorouracil as maintenance therapy. Thirty-seven patients were inoperable and 39 had the primary tumour resected with histological evidence of residual disease. Survival in the inoperable group was short and showed no significant difference between treated and control patients. The median survival times for treated and control groups were 9.5 and 9.0 weeks respectively. In the resected patients there was no difference in ultimate overall survival between the groups but up to 20 weeks there was a suggestion that the probability of survival in treated patients was higher (P=0.06). The patients were well-matched and it is concluded that chemotherapy has had an early effect but that a further trial with more detailed stratification, particularly of staging and histological grade, is needed. No patient received treatment for longer than two years and unacceptable toxicity occurred in only two patients. Nausea occurred more frequently in the treated group but was short-lived and clinically manageable.